• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

增加水的摄入量能否预防常染色体显性遗传性多囊肾病的疾病进展?

Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease?

作者信息

Higashihara Eiji, Nutahara Kikuo, Tanbo Mitsuhiro, Hara Hidehiko, Miyazaki Isao, Kobayashi Kuninori, Nitatori Toshiaki

机构信息

Department of ADPKD Research, Kyorin University School of Medicine, Tokyo, Japan Department of Urology, Kyorin University School of Medicine, Tokyo, Japan.

Department of Urology, Kyorin University School of Medicine, Tokyo, Japan.

出版信息

Nephrol Dial Transplant. 2014 Sep;29(9):1710-9. doi: 10.1093/ndt/gfu093. Epub 2014 Apr 15.

DOI:10.1093/ndt/gfu093
PMID:24739484
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4145867/
Abstract

BACKGROUND

The clinical effects of increased water intake on autosomal dominant polycystic kidney disease (ADPKD) progression are unknown.

METHODS

ADPKD patients with creatinine clearance ≧ 50 mL/min/1.73 m(2) were divided into high (H-, n = 18) and free (F-, n = 16) water-intake groups, mainly according to their preference. Prior to the study, 30 patients underwent annual evaluation of total kidney volume (TKV) and 24-h urine for an average of 33 months. During the 1-year study period, TKV and 24-h urine were analyzed at the beginning and end of the study and every 4 months, respectively.

RESULTS

During the pre-study period, urine volume (UV) in the H-group was higher (P = 0.034), but TKV and kidney function and their slopes were not significantly different between the two groups. After the study commenced, UV further increased (P < 0.001) in the H-group but not in the F-group. During the study period, TKV and kidney function slopes were not significantly different between the two groups (primary endpoint). Plasma copeptin was lower (P = 0.024) in the H-group than in the F-group. TKV and kidney function slopes became worse (P = 0.047 and 0.011, respectively) after high water intake (H-group) but not in the F-group. High UV was associated with increased urine sodium, and urine sodium positively correlated with the % TKV slope (P = 0.014).

CONCLUSIONS

Although the main endpoint was not significant, high water intake enhanced disease progression in the H-group when compared with the pre-study period. These findings necessitate a long-term randomized study before drawing a final conclusion.

摘要

背景

增加水摄入量对常染色体显性多囊肾病(ADPKD)进展的临床影响尚不清楚。

方法

肌酐清除率≧50 mL/min/1.73 m²的ADPKD患者主要根据其偏好分为高水摄入量组(H组,n = 18)和自由水摄入量组(F组,n = 16)。在研究前,30名患者平均33个月接受一次总肾体积(TKV)和24小时尿液的年度评估。在1年的研究期间,分别在研究开始和结束时以及每4个月分析一次TKV和24小时尿液。

结果

在研究前期,H组的尿量(UV)较高(P = 0.034),但两组之间的TKV、肾功能及其斜率无显著差异。研究开始后,H组的UV进一步增加(P < 0.001),而F组没有。在研究期间,两组之间的TKV和肾功能斜率无显著差异(主要终点)。H组的血浆 copeptin低于F组(P = 0.024)。高水摄入量(H组)后TKV和肾功能斜率变差(分别为P = 0.047和0.011),而F组没有。高UV与尿钠增加相关,尿钠与TKV斜率百分比呈正相关(P = 0.014)。

结论

虽然主要终点不显著,但与研究前期相比,高水摄入量在H组中加速了疾病进展。在得出最终结论之前,这些发现需要进行长期随机研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e55/4145867/dc57acf5673f/gfu09306.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e55/4145867/5672d612dc14/gfu09301.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e55/4145867/a32bf4c33623/gfu09302.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e55/4145867/2345dbf3483a/gfu09303.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e55/4145867/c0f2e635f202/gfu09304.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e55/4145867/ac7d26978779/gfu09305.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e55/4145867/dc57acf5673f/gfu09306.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e55/4145867/5672d612dc14/gfu09301.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e55/4145867/a32bf4c33623/gfu09302.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e55/4145867/2345dbf3483a/gfu09303.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e55/4145867/c0f2e635f202/gfu09304.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e55/4145867/ac7d26978779/gfu09305.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e55/4145867/dc57acf5673f/gfu09306.jpg

相似文献

1
Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease?增加水的摄入量能否预防常染色体显性遗传性多囊肾病的疾病进展?
Nephrol Dial Transplant. 2014 Sep;29(9):1710-9. doi: 10.1093/ndt/gfu093. Epub 2014 Apr 15.
2
Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.托伐普坦对不同肾功能水平常染色体显性多囊肾病个体的短期疗效。
Am J Kidney Dis. 2015 Jun;65(6):833-41. doi: 10.1053/j.ajkd.2014.11.010. Epub 2015 Jan 15.
3
Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease.常染色体显性多囊肾病中肾血流的磁共振测量与疾病进展
Clin J Am Soc Nephrol. 2007 Jan;2(1):112-20. doi: 10.2215/CJN.00910306. Epub 2006 Nov 2.
4
Kidney volume and function in autosomal dominant polycystic kidney disease.常染色体显性多囊肾病中的肾脏体积与功能
Clin Exp Nephrol. 2014 Feb;18(1):157-65. doi: 10.1007/s10157-013-0834-4. Epub 2013 Jul 18.
5
Urine and plasma osmolality in patients with autosomal dominant polycystic kidney disease: reliable indicators of vasopressin activity and disease prognosis?常染色体显性多囊肾病患者的尿液和血浆渗透压:血管加压素活性及疾病预后的可靠指标?
Am J Nephrol. 2015;41(3):248-56. doi: 10.1159/000382081. Epub 2015 Apr 25.
6
Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. copeptin,精氨酸加压素的替代标志物,与常染色体显性多囊肾病患者的总肾体积变化和 GFR 下降的关系:来自 CRISP 队列的结果。
Am J Kidney Dis. 2013 Mar;61(3):420-9. doi: 10.1053/j.ajkd.2012.08.038. Epub 2012 Oct 22.
7
A rapid high-performance semi-automated tool to measure total kidney volume from MRI in autosomal dominant polycystic kidney disease.一种快速高效的半自动工具,用于从 MRI 测量常染色体显性多囊肾病的总肾体积。
Eur Radiol. 2019 Aug;29(8):4188-4197. doi: 10.1007/s00330-018-5918-9. Epub 2019 Jan 21.
8
Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD).常染色体显性多囊肾病中肾功能下降和肾体积增长的预测因素:一项前瞻性队列研究(日本多囊肾病登记处:J-PKD)
Clin Exp Nephrol. 2021 Sep;25(9):970-980. doi: 10.1007/s10157-021-02068-x. Epub 2021 Apr 29.
9
Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.托伐普坦治疗常染色体显性多囊肾病患者时与总肾体积增长率无关的肾功能保存。
Clin Exp Nephrol. 2021 May;25(5):467-478. doi: 10.1007/s10157-020-02009-0. Epub 2021 Jan 20.
10
Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).精氨酸加压素替代标志物尿 copeptin 与常染色体显性多囊肾病(ADPKD)严重程度的关联。
Clin Exp Nephrol. 2015 Dec;19(6):1199-205. doi: 10.1007/s10157-015-1101-7. Epub 2015 Feb 27.

引用本文的文献

1
Potential Add-On Benefits of Dietary Intervention in the Treatment of Autosomal Dominant Polycystic Kidney Disease.饮食干预治疗常染色体显性遗传性多囊肾病的潜在附加益处。
Nutrients. 2024 Aug 6;16(16):2582. doi: 10.3390/nu16162582.
2
Low daily water intake profile-is it a contributor to disease?低日饮水量——它是疾病的诱因吗?
Nutr Health. 2024 Sep;30(3):435-446. doi: 10.1177/02601060241238826. Epub 2024 Mar 22.
3
Thirst intensity survey in ADPKD patients.ADPKD 患者口渴强度调查。

本文引用的文献

1
Kidney volume and function in autosomal dominant polycystic kidney disease.常染色体显性多囊肾病中的肾脏体积与功能
Clin Exp Nephrol. 2014 Feb;18(1):157-65. doi: 10.1007/s10157-013-0834-4. Epub 2013 Jul 18.
2
Tolvaptan in patients with autosomal dominant polycystic kidney disease.托伐普坦治疗常染色体显性遗传多囊肾病。
N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3.
3
GFR estimation using standardized serum cystatin C in Japan.基于血清胱抑素 C 的标准化估算肾小球滤过率在日本的应用。
Clin Exp Nephrol. 2023 Oct;27(10):819-827. doi: 10.1007/s10157-023-02373-7. Epub 2023 Jun 23.
4
Nonpharmacological Management of Autosomal Dominant Polycystic Kidney Disease.常染色体显性遗传性多囊肾病的非药物治疗。
Adv Kidney Dis Health. 2023 May;30(3):220-227. doi: 10.1053/j.akdh.2022.12.008.
5
Identifying the main predictors of urine output in autosomal-dominant polycystic kidney disease (ADPKD) patients taking tolvaptan.鉴定服用托伐普坦的常染色体显性遗传多囊肾病(ADPKD)患者尿量的主要预测因素。
Int Urol Nephrol. 2023 Oct;55(10):2629-2637. doi: 10.1007/s11255-023-03555-8. Epub 2023 Mar 23.
6
Dietary Aspects and Drug-Related Side Effects in Autosomal Dominant Polycystic Kidney Disease Progression.常染色体显性遗传性多囊肾病进展中的饮食相关问题和药物相关副作用。
Nutrients. 2022 Nov 3;14(21):4651. doi: 10.3390/nu14214651.
7
The wind of change in the management of autosomal dominant polycystic kidney disease in childhood.儿童常染色体显性遗传性多囊肾病管理的变革之风。
Pediatr Nephrol. 2022 Mar;37(3):473-487. doi: 10.1007/s00467-021-04974-4. Epub 2021 Mar 7.
8
Predictors of progression in autosomal dominant and autosomal recessive polycystic kidney disease.常染色体显性遗传多囊肾病和常染色体隐性遗传多囊肾病进展的预测因素。
Pediatr Nephrol. 2021 Sep;36(9):2639-2658. doi: 10.1007/s00467-020-04869-w. Epub 2021 Jan 21.
9
Hydration for health hypothesis: a narrative review of supporting evidence.健康水合作用假说:支持证据的叙述性综述
Eur J Nutr. 2021 Apr;60(3):1167-1180. doi: 10.1007/s00394-020-02296-z. Epub 2020 Jul 6.
10
ADPKD current management and ongoing trials.ADPKD 的现行治疗方法和正在进行的试验。
J Nephrol. 2020 Apr;33(2):223-237. doi: 10.1007/s40620-019-00679-y. Epub 2019 Dec 18.
Am J Kidney Dis. 2013 Feb;61(2):197-203. doi: 10.1053/j.ajkd.2012.07.007. Epub 2012 Aug 11.
4
Endogenous concentrations of ouabain act as a cofactor to stimulate fluid secretion and cyst growth of in vitro ADPKD models via cAMP and EGFR-Src-MEK pathways.内源性哇巴因浓度作为辅助因子,通过 cAMP 和 EGFR-Src-MEK 途径刺激体外 ADPKD 模型的液体分泌和囊肿生长。
Am J Physiol Renal Physiol. 2012 Oct;303(7):F982-90. doi: 10.1152/ajprenal.00677.2011. Epub 2012 Aug 1.
5
Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease. copeptin,一种加压素的替代标志物,与常染色体显性多囊肾病患者的肾功能下降有关。
Nephrol Dial Transplant. 2012 Nov;27(11):4131-7. doi: 10.1093/ndt/gfs070. Epub 2012 Apr 20.
6
Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.血管加压素、 copeptin 和肾功能正常的常染色体显性多囊肾病患者的肾浓缩能力。
Clin J Am Soc Nephrol. 2012 Jun;7(6):906-13. doi: 10.2215/CJN.11311111. Epub 2012 Apr 19.
7
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.常染色体显性遗传性多囊肾病的肾脏体积和功能结局。
Clin J Am Soc Nephrol. 2012 Mar;7(3):479-86. doi: 10.2215/CJN.09500911. Epub 2012 Feb 16.
8
Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.托伐普坦治疗常染色体显性遗传多囊肾病:三年经验。
Clin J Am Soc Nephrol. 2011 Oct;6(10):2499-507. doi: 10.2215/CJN.03530411. Epub 2011 Sep 8.
9
Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease.血管加压素在慢性肾脏病、特别是常染色体显性遗传多囊肾病中的潜在有害作用。
Kidney Blood Press Res. 2011;34(4):235-44. doi: 10.1159/000326902. Epub 2011 Jun 21.
10
Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.托伐普坦对常染色体显性多囊肾病患者肾功能和容量的短期影响。
Kidney Int. 2011 Aug;80(3):295-301. doi: 10.1038/ki.2011.119. Epub 2011 May 4.